EPITOMICS Trademark

Trademark Overview

On Friday, April 25, 2003, a trademark application was filed for EPITOMICS with the United States Patent and Trademark Office. The USPTO has given the EPITOMICS trademark a serial number of 76509356. The federal status of this trademark filing is REGISTERED AND RENEWED as of Friday, August 22, 2014. This trademark is owned by Epitomics, Inc.. The EPITOMICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Technical consultation and research in the field of biochemistry, namely, the development of technology for the production of monoclonal antibodies and the production of monoclonal antibodies for research, diagnostic, [ and therapeutic ] purposes
epitomics

General Information

Serial Number76509356
Word MarkEPITOMICS
Filing DateFriday, April 25, 2003
Status800 - REGISTERED AND RENEWED
Status DateFriday, August 22, 2014
Registration Number2876495
Registration DateTuesday, August 24, 2004
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, June 1, 2004

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesTechnical consultation and research in the field of biochemistry, namely, the development of technology for the production of monoclonal antibodies and the production of monoclonal antibodies for research, diagnostic, [ and therapeutic ] purposes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 13, 2003
Primary Code042
First Use Anywhere DateSunday, March 31, 2002
First Use In Commerce DateSunday, March 31, 2002

Trademark Owner History

Party NameEpitomics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBurlingame, CA 940101303
Party NameEpitomics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressBurlingame, CA 940101303
Party NameEpitomics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBurlingame, CA 940101303

Trademark Events

Event DateEvent Description
Thursday, August 24, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Thursday, September 19, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 20, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, January 20, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, August 22, 2014NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Friday, August 22, 2014REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Friday, August 22, 2014REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Friday, August 22, 2014CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Tuesday, August 5, 2014TEAS SECTION 8 & 9 RECEIVED
Thursday, September 19, 2013ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, September 19, 2013TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, December 28, 2010TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, September 8, 2010REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Wednesday, September 8, 2010CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, August 19, 2010TEAS SECTION 8 & 15 RECEIVED
Tuesday, August 24, 2004REGISTERED-PRINCIPAL REGISTER
Tuesday, June 1, 2004PUBLISHED FOR OPPOSITION
Wednesday, May 12, 2004NOTICE OF PUBLICATION
Monday, March 1, 2004APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, December 15, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 15, 2003PAPER RECEIVED
Monday, November 24, 2003PAPER RECEIVED
Wednesday, November 12, 2003CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 12, 2003PAPER RECEIVED
Friday, October 24, 2003NON-FINAL ACTION MAILED
Friday, September 26, 2003ASSIGNED TO EXAMINER

Related Keywords

epitomics production research monoclonal antibodies therapeutic purposes diagnostic development field consultation